Eisai Co., Ltd. (ESAIY)
OTCMKTS
· Delayed Price · Currency is USD
6.39
+0.14 (2.24%)
May 16, 2025, 3:58 PM EDT
Eisai Revenue
In the fiscal year ending March 31, 2025, Eisai had annual revenue of 789.40B JPY with 6.42% growth. Eisai had revenue of 188.24B in the quarter ending March 31, 2025, a decrease of -1.19%.
Revenue
789.40B JPY
Revenue Growth
+6.42%
P/S Ratio
1.37
Revenue / Employee
71.33M JPY
Employees
11,067
Market Cap
7.21B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 789.40B | 47.65B | 6.42% |
Mar 31, 2024 | 741.75B | -2.65B | -0.36% |
Mar 31, 2023 | 744.40B | -11.82B | -1.56% |
Mar 31, 2022 | 756.23B | 110.28B | 17.07% |
Mar 31, 2021 | 645.94B | -49.68B | -7.14% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.73B |
Veradigm | 588.02M |
Tian'an Technology Group | 1.78M |
Glass House Brands | 215.62M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
Silence Therapeutics | 27.70M |
Eisai News
- 1 day ago - Eisai Co., Ltd. (ESALF) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease - Reuters
- 2 months ago - EU regulator not updating opinion on Eisai-Biogen's Alzheimer's drug - Reuters
- 2 months ago - Eisai: Will Have No Problem Hitting Leqembi Forecasts - Seeking Alpha
- 3 months ago - Eisai Co., Ltd. (ESALF) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Europe to review safety data for Eisai-Biogen Alzheimer's drug - Reuters
- 3 months ago - US FDA OKs monthly maintenance dosing for Eisai/Biogen's Alzheimer's drug - Reuters
- 4 months ago - Merck and Eisai's cancer drugs fail to improve overall survival in late-stage trial - Reuters